Announcement on Amending Some Governance Systems of the Company
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
The board approved several revisions to improve operational standards and internal controls.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Earlier from RemeGen
- Announcement on 1st Vesting Result of the 1st Vesting Period for the Reserved Grant of Type B Interests under the 2022 A-share Restricted Stock Incentive Plan and Lifting of Trading Restrictions
- Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
- Announcement on Resolutions of the 30th Meeting of the 2nd Board of Directors
- Announcement on Estimated Daily Related Party Transactions in 2026-2028
- ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
Later from RemeGen
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 32nd Meeting of the 2nd Board of Directors
- Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
- Announcement on Canceling Some Restricted Stock Granted but Not Yet Vested in 2022 A-share Restricted Stock Incentive Plan
Follow RemeGen into a list and get an email when it puts out news.
Follow RemeGen